Source: Medical Economics
Excerpt:
The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) announced their intent to initiate scheduling of 7-hydroxymitragynine (7-OH), a kratom-derived compound, under the Controlled Substances Act. On July 29, officials suggested placing 7-OH in Schedule I, a classification traditionally reserved for substances with a high potential for abuse, no currently accepted medical use, and no established safety margin.
Such a move would have sweeping consequences for clinical research, product regulation, and patient access. Yet no evidence was presented to support it.